These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24789783)

  • 21. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models.
    Khodai T; Chappell D; Christy C; Cockle P; Eyles J; Hammond D; Gore K; McCluskie MJ; Evans DM; Lang S; Loudon PT; Townend T; Wright P; West K; Bright H
    Clin Vaccine Immunol; 2011 Oct; 18(10):1702-9. PubMed ID: 21852545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays.
    Blevins TP; Yu Y; Belshe RB; Bellamy AR; Morrison LA
    PLoS One; 2019; 14(4):e0214467. PubMed ID: 30946751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.
    Awasthi S; Shaw C; Friedman H
    Expert Rev Vaccines; 2014 Dec; 13(12):1475-88. PubMed ID: 25138572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.
    Du R; Wang L; Xu H; Wang Z; Zhang T; Wang M; Ning Y; Deng F; Hu Z; Wang H; Li Y
    Antiviral Res; 2017 Nov; 147():131-141. PubMed ID: 29061442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Construction and Immunogenicity Analysis of Herpes Simplex Virus Type 2 Glycoprotein D Recombinant Adenovirus Vaccine].
    Liu W; Zhao D; Wang Z; Li Y; Wang H; Wang H
    Bing Du Xue Bao; 2016 May; 32(3):267-72. PubMed ID: 29962197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human sera.
    Luo Y; Xiong D; Li HH; Qiu SP; Lin CL; Chen Q; Huang CH; Yuan Q; Zhang J; Xia NS
    Virol J; 2016 Mar; 13():44. PubMed ID: 26987753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone.
    Meseda CA; Elkins KL; Merchlinsky MJ; Weir JP
    J Infect Dis; 2002 Oct; 186(8):1065-73. PubMed ID: 12355355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.
    Krawczyk A; Krauss J; Eis-Hübinger AM; Däumer MP; Schwarzenbacher R; Dittmer U; Schneweis KE; Jäger D; Roggendorf M; Arndt MA
    J Virol; 2011 Feb; 85(4):1793-803. PubMed ID: 21123390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine.
    Ashley RL; Crisostomo FM; Doss M; Sekulovich RE; Burke RL; Shaughnessy M; Corey L; Polissar NL; Langenberg AG
    J Infect Dis; 1998 Jul; 178(1):1-7. PubMed ID: 9652416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with combined HSV-2 glycoproteins B2 : D2 gene DNAs: protection against lethal intravaginal challenges in mice.
    Lee HH; Cha SC; Jang DJ; Lee JK; Choo DW; Kim YS; Uh HS; Kim SY
    Virus Genes; 2002 Oct; 25(2):179-88. PubMed ID: 12416680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization.
    Komala Sari T; Gianopulos KA; Nicola AV
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31826995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs.
    Awasthi S; Hook LM; Shaw CE; Pahar B; Stagray JA; Liu D; Veazey RS; Friedman HM
    PLoS Pathog; 2017 Jan; 13(1):e1006141. PubMed ID: 28103319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial.
    Leroux-Roels G; Clément F; Vandepapelière P; Fourneau M; Heineman TC; Dubin G
    Hum Vaccin Immunother; 2013 Jun; 9(6):1254-62. PubMed ID: 23434737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.
    Awasthi S; Lubinski JM; Shaw CE; Barrett SM; Cai M; Wang F; Betts M; Kingsley S; Distefano DJ; Balliet JW; Flynn JA; Casimiro DR; Bryan JT; Friedman HM
    J Virol; 2011 Oct; 85(20):10472-86. PubMed ID: 21813597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of anti-glycoproteins D (anti-gD) and K (anti-gK) IgGs in pathology of herpes stromal keratitis in humans.
    Mott KR; Osorio Y; Maguen E; Nesburn AB; Wittek AE; Cai S; Chattopadhyay S; Ghiasi H
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2185-93. PubMed ID: 17460278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects.
    Criscuolo E; Castelli M; Diotti RA; Amato V; Burioni R; Clementi M; Ambrosi A; Mancini N; Clementi N
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of neutralization of herpes simplex virus by antibodies directed at the fusion domain of glycoprotein B.
    Cairns TM; Fontana J; Huang ZY; Whitbeck JC; Atanasiu D; Rao S; Shelly SS; Lou H; Ponce de Leon M; Steven AC; Eisenberg RJ; Cohen GH
    J Virol; 2014 Mar; 88(5):2677-89. PubMed ID: 24352457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The major neutralizing antigenic site on herpes simplex virus glycoprotein D overlaps a receptor-binding domain.
    Whitbeck JC; Muggeridge MI; Rux AH; Hou W; Krummenacher C; Lou H; van Geelen A; Eisenberg RJ; Cohen GH
    J Virol; 1999 Dec; 73(12):9879-90. PubMed ID: 10559300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.
    Bernstein DI; Cardin RD; Bravo FJ; Hamouda T; Pullum DA; Cohen G; Bitko V; Fattom A
    Vaccine; 2019 Oct; 37(43):6470-6477. PubMed ID: 31515143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.